Apyx Medical (NASDAQ: APYX) director receives 50,000 stock options at $4.65 strike

Rhea-AI Filing Summary

Apyx Medical Corp director Lawrence Waldman received a grant of stock options as compensation. He was awarded options to buy 50,000 shares of common stock at an exercise price of $4.6500 per share, expiring on June 11, 2036. According to the terms, the option vests ratably over a 12‑month period and becomes fully vested and fully exercisable on the first anniversary of the grant date. Following this award, Waldman holds 50,000 stock options directly under this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Waldman Lawrence

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Option to Buy)	50,000	$0.00	--

Holdings After Transaction: Stock Option (Option to Buy) — 50,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 50,000 options Exercise price: $4.6500 per share Expiration date: June 11, 2036 +2 more

5 metrics

Options granted 50,000 options Stock option grant to director on June 11, 2026

Exercise price $4.6500 per share Strike price of granted stock options

Expiration date June 11, 2036 Option expiration for the 50,000 granted options

Post-grant derivative holdings 50,000 options Total derivative securities beneficially owned following transaction

Vesting period 12 months Options vest ratably and are fully exercisable after one year

Key Terms

Stock Option (Option to Buy), exercise price, Grant, award, or other acquisition, vest ratably, +1 more

5 terms

Stock Option (Option to Buy) financial

"security_title: Stock Option (Option to Buy)"

exercise price financial

"conversion_or_exercise_price: 4.6500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vest ratably financial

"option which shall vest ratably over a twelve (12) month period"

fully exercisable financial

"shall become fully vested and fully exercisable on the first anniversary"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Waldman Lawrence

(Last) (First) (Middle)

C/O APYX MEDICAL CORPORATION

5115 ULMERTON ROAD

(Street)

CLEARWATER FLORIDA 33760

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apyx Medical Corp [ APYX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Option to Buy)	$4.65	06/11/2026		A		50,000		(1)	06/11/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. Reporting person was granted a stock option which shall vest ratably over a twelve (12) month period and shall become fully vested and fully exercisable on the first anniversary of the date of grant.

	/s/ Lawrence J. Waldman	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Apyx Medical Corp (APYX) disclose for Lawrence Waldman?

Apyx Medical Corp reported that director Lawrence Waldman received a grant of stock options. The award covers 50,000 options to buy common stock at an exercise price of $4.6500 per share, expiring June 11, 2036, as part of his compensation package.

How many Apyx Medical (APYX) stock options were granted to Lawrence Waldman?

Lawrence Waldman was granted 50,000 stock options in Apyx Medical. These options give him the right to purchase up to 50,000 shares of common stock at a fixed $4.6500 exercise price, subject to vesting over a 12‑month period from the grant date.

What are the vesting terms of Lawrence Waldman’s APYX stock option grant?

The stock option grant to Lawrence Waldman vests ratably over twelve months. According to the terms, portions of the 50,000 options vest each month, and the award becomes fully vested and fully exercisable on the first anniversary of the June 11, 2026 grant date.

What is the exercise price and expiration date of Waldman’s Apyx Medical options?

Waldman’s options have an exercise price of $4.6500 per share and expire June 11, 2036. This means he can purchase Apyx Medical common stock at $4.6500, once vested, any time before the June 2036 expiration, provided he meets the grant’s conditions.

Is Lawrence Waldman’s APYX stock option grant a market purchase or compensation award?

The Form 4 shows Waldman’s transaction as a grant or award acquisition, not an open‑market purchase. Code “A” and the footnote indicate he received 50,000 stock options as compensation, vesting over 12 months and becoming fully exercisable on the first anniversary.

How many Apyx Medical stock options does Waldman hold after this grant?

After the reported grant, Waldman holds 50,000 stock options directly from this award. The Form 4 shows total derivative securities beneficially owned following the transaction as 50,000 options, representing this single compensation grant with a $4.6500 exercise price and June 11, 2036 expiration.